Is First Wave BioPharma Inc (FWBI) Stock About to Get Hot Monday?

The market has been down on First Wave BioPharma Inc (FWBI) stock recently. FWBI gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

First Wave BioPharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on FWBI!

See Full FWBI Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With FWBI Stock Today?

First Wave BioPharma Inc (FWBI) stock is trading at $1.37 as of 2:02 PM on Monday, Sep 26, of $0.00, or 0% from the previous closing price of $1.37. Volume today is less active than usual. So far 369,658 shares have traded compared to average volume of 1,560,033 shares. The stock has traded between $1.32 and $1.53 so far today. To screen for more stocks like First Wave BioPharma Inc click here.

More About First Wave BioPharma Inc

First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Click Here to get the full Stock Report for First Wave BioPharma Inc stock.